维普中文期刊产品整合服务
94篇 您的检索式:作者名="Tan ML"
    题名 作者 年代 出处 被引量
1Prospective validation of %p2PSA and the Prostate Health Index, in prostate cancer detection in initial prostate biopsies of Asian men, with total PSA 4-10 ng ml-1显示文摘尽管有它为屏蔽的前列腺癌症的普遍使用,低特性使 PSA 成为非最优的 biomarker,特别在 4-10 ng ml 1 的诊断灰色的地区。假积极与伴随的病态导致不必要的活体检视。这在与在 4.0 和 10 ng ml 1 之间的全部的 PSA 介绍的亚洲人是 % p2PSA 和前列腺健康索引(PHI ) 的第一未来的确认研究。我们学习了在 50 和 75 岁之间的 157 个亚洲人,与每直肠的前列腺考试的正常,经历他们的第一前列腺活体检视,用一个标准化活体检视协议,为 4-10 ng ml 1 的 PSA 层次。(19.1%) 三十被发现在活体检视上有前列腺癌症。有或没有前列腺癌症的病人之间的统计上重要的差别被作出对有利的裁决全部的 PSA, p2PSA, % p2PSA,和 PHI。在为全部的 PSA, % fPSA, % p2PSA,和 PHI 操作典型曲线的接收装置的曲线下面的区域分别地是 0.479, 0.420, 0.695,和 0.794。PHI 最好预言 prostatic 活体检视结果。在 90% 的敏感, PHI 的特性(95% CI ) 是 58.3% ,多于在 17.3% 点使全部的 PSA 的特性增加两倍,潜在地避免 77 (49%) 不必要的活体检视。类似于研究在主要白种人人口,我们有希望地证明了 % p2PSA 和 PHI 极大地超过总数并且释放总计 PSA 比率,在前列腺癌症的察觉起初活体检视。更高的 PHI 层次也对应于增加检测 GS 7 癌症的风险。我们验证了 PHI 的使用与在 4 和 10 ng ml 1 之间的浆液 PSA 在亚洲人关于前列腺活体检视帮助决策。Lincoln GL Tan Yung Khan Tan Bee Choo Tai Karen ML Tan Vineet Gauhar Ho Yee Tiong Robert CW Hawkins Thomas P Thamboo Felicia SK Hong Edmund Chiong 2017Asian Journal of Andrology2017,19,3:13
2Effet of Maotai liguor in inducing metallothioneins and on hepatic stellate cells显示文摘Cheng ML Wu J Wang HQ Xue LM Tan YZ Liu P Li CX Huang NH Yao YM Ren LZ Ye L Li L Jia ML 2001Shijie Huaren Xiaohua Zazhi2001,9,12:2
3Entry and early events of severe acute respiratory syndrome coronavirus 显示文摘Ng ML Tan SH See EE 2003J Med Virol2003,71,:1
4Anti-chondrosarcoma effects of PEDF mediated via molecules important to apoptosis, cell cycling, adhesion and invasion 显示文摘Tan ML Choong PFM Dass CR 2010Biophys ResCommun2010,398,4:1
5The controlled differentiation of human neural stem cells into TH2 immunoreactive (ir) neurons in vitro 显示文摘Jin GH Tan XF Tian ML 2005Neurosci Lett2005,386,1:1
6Idiopathic paroxysmal kinesigenic dyskinesia in Malaysia,a multi-racial Southeast Asian country显示文摘Tai ML Lim SY Tan CT 2010J Clin Neuroscience2010,17,8:1
7Idiopathic paroxysmal kinesigenic dyskinesia in Malaysia, a multi-racial Southeast Asian country显示文摘Tai ML Lim SY Tan CT 2010J Clin Neurosci2010,17,:1
8Acute pediatric rhabdomyolysis: causes and rates of renal failure 显示文摘Mannix R Tan ML Wright R 2006Pediatrics2006,118,5:1
9The tissue effects of ultrasound--assisted lipoplasty 显示文摘 Robinson JB Beran SJ Tan J Howard BK Zocchi ML Rohrich RJ 1998Plast Reconstr Surg1998,102,1:1
10显示文摘 Ong CN Tan TC 1992Trop Geogr Med1992,44,4:1
11The mTOR signalling pathway in cancer and the potential mTOR inhibitory activities of natural phytochemicals 显示文摘Tan HK Moad AI Tan ML 2014Asian Pac J Cancer Prev2014,15,:1
12Cancer,chitosan nanoparticles and catalytic nucleic acids显示文摘Tan ML Choong PF Dass CR 2009J Pharm Pharmacol2009,61,1:1
13Cancer stem cell and epi- thelial-mesenchymal transition markers predict worse outcome in metaplastic carcinoma of the breast 显示文摘Oon ML Thike AA Tan SY 2015Breast Cancer Res Treat2015,150,1:1
14Superficial parotideetomy via facelift incision显示文摘Lohuis PJ Tan ML Bonte K 2009Ann Otol Rhinol Laryngol2009,118,4:1
15Cadmium level in seminal ptasma may affect the pregnancy rate for patients undergoing infertility evaluation and treatment显示文摘Wu HM Lin -Tan DT Wang ML 2008Reprod Toxicol2008,25,4:1
16Acute pediatric rhabdomyolysis:causes and rates of renal failure显示文摘Mannix R Tan ML Wright R 0,,05:1
17A Test of the Persistence in the Performance of UK Managed Funds 显示文摘Allen D E ML Tan 1999Journal of Business Finance and Accounting1999,26,:1
18Report of the Council On Scientifie Affais : Preventing needlestick injuries in health care settings 显示文摘Tan L Hawk JC Sterling ML 2001Axch Internal Med2001,161,9:1
19Multi-resistantAcinetobacterbau-man- nii on a bums unit-clinical risk factors and prognosis 显示文摘Wong TH Tan BH Ling ML 2002Burns2002,28,6:1
20Programmed cell death pathways and current antitumor targets显示文摘Tan ML Ooi JP Ismail N 2009Pharm Res2009,26,7:1
返回顶部 每页显示:
共5页 首页 上一页 第1页 下一页 末页 /5 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费